Longer treatment duration with SLIT leads to higher patient satisfaction and clinical improvement. Outcomes of the SAMITES study

Martı́, Enric; Sánchez-Salguero, C.; Scorza, Enrique; Garcia, Mario

doi:10.1186/2045-7022-3-s2-p12

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who had a longer treatment period were more compliant then those who had shorter treatment, and patient satisfaction was related to better adherence [66].…”

Section: Causes Related To Treatmentmentioning

confidence: 95%

Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved?

Senna

Caminati

Lockey

2014

Curr Treat Options Allergy

View full text Add to dashboard Cite

Opinion StatementAllergen immunotherapy (AIT) is the only available causal treatment for allergic respiratory diseases; however, data demonstrate a high discontinuation rate for both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). The complex mechanism of action of allergen immunotherapy (AIT) includes an interaction of innate and adaptive immune processes, resulting in immune tolerance, as illustrated by a decrease in specific immunoglobulin (Ig)-E, an increase in specific IgG1 and IgG4, and inhibition of inflammation involving mast cells, basophils, and eosinophils. This induction of immune tolerance leads to a significant improvement in symptoms and decreased medication scores. A 3-to 5-year course of AIT is required to obtain this disease-modifying effect, which substantially differentiates AIT frompharmacologic treatment. A carry-over effect can persist for up to 12 years. Furthermore, AIT may prevent the onset of asthma in patients with allergic rhinitis, as well as decreasing the onset of new sensitizations to inhalant allergens. Several meta-analyses and controlled studies, involving adult and pediatric subjects, have indicated that both sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) are relatively safe, effective, and well tolerated. AIT may also have a positive impact on the cost to the healthcare system, as evidence indicates the cost-benefit of such treatment. Adherence to AIT is crucial for a positive clinical outcome and non-adherence represents a major drawback for such therapy. It actually concerns not only AIT but also various pharmacologic treatments for allergic respiratory diseases, as well as for other chronic illnesses. The issue of non-adherence is an emerging and worldwide problem for chronic diseases and could be an important factor responsible for an overall decrease in treatment efficacy and increased rates of hospitalization, morbidity, and mortality. This review provides an overview of the different reasons that may account for the low adherence rate for AIT. Some of these reasons can be related to the patient's age when they begin such therapy, the allergic disease being treated, and questions about the efficacy, costs, inconvenience, and safety of AIT. Well-structured educational programs,especially by healthcare professionals, the print media, and the Internet, are needed to improve adherence to AIT.

show abstract

“…Patients who had a longer treatment period were more compliant then those who had shorter treatment, and patient satisfaction was related to better adherence [66].…”

Section: Causes Related To Treatmentmentioning

confidence: 95%

Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved?

Senna

Caminati

Lockey

2014

Curr Treat Options Allergy

View full text Add to dashboard Cite

show abstract

“…In the present study, the levels of patient satisfaction with SLIT were moderate to good. There are few directly comparative, detailed data in this field, although a few SLIT- or AIT-specific questionnaires have recently been developed and validated [ 20 , 21 , 27 – 30 ]. However, many studies have sought to determine levels of patient satisfaction, and these are generally correlated with the degree of symptom relief.…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump

Reig

Casas

Fernández

et al. 2021

Drugs - Real World Outcomes

View full text Add to dashboard Cite

Background Convenient dosing is a key component of treatment adherence and thus efficacy and safety. Aqueous sublingual immunotherapy (SLIT) formulations can be administered with a dosing pump that delivers 200 µL of volume per actuation. Objective The objective of this study was to describe the use of Staloral ® 300 Rapid in its new dosing pump presentation and to evaluate the safety and satisfaction from both the patient and doctor. Patients and Methods We performed a retrospective non-interventional study in a population (aged 5 years or over) of individuals with allergic rhinitis or allergic asthma who were being treated with aqueous 300 index of reactivity SLIT formulations of various allergens (grass pollen, tree pollen, house dust mites). Based on a detailed, SLIT-specific, patient self-questionnaire (Quartis ® ) and the inspection of medical records, we assessed the characteristics of the SLIT, safety, patient satisfaction and willingness to continue SLIT. The physician’s satisfaction with the treatment was measured on a 0–100 visual analogue scale. Adverse events were coded with the Medical Dictionary for Regulatory Activities. Results A total of 801 valid patients were included (52.4% male; mean ± standard deviation age: 25.9 ± 17.2 years; mean time since diagnosis: 4.56 ± 4.68 years; mean time using the previous dosing pump: 19.2 ± 13.0 months; time using the 200-µL dosing pump: 14.95 ± 3.80 months). Among the study population, 317 subjects comprised the paediatric subgroup (57%: male; mean age: 9.8 ± 2.5 years). Overall, 54 patients (6.7%) reported a total of 68 adverse events (including 51 gastrointestinal adverse events). The large majority of adverse events were mild, local and transient and did not require treatment. There were no severe adverse events. The level of patient satisfaction with the ease of SLIT administration was high (84.3% overall, and 82.6% in the paediatric subgroup). The mean ± standard deviation visual analogue scale score for physician satisfaction with the treatment was 70.6 ± 25.1 out of 100. Conclusions Administration of 300 index of reactivity SLIT with a 200-µL dosing pump is safe, well tolerated and associated with good levels of patient satisfaction.

show abstract

Allergy Immunotherapy Adherence and Delivery Route: Location Does Not Matter

Cox¹,

Hankin²,

Lockey³

2014

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

Longer treatment duration with SLIT leads to higher patient satisfaction and clinical improvement. Outcomes of the SAMITES study

Cited by 3 publications

References 0 publications

Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved?

Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved?

A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump

Allergy Immunotherapy Adherence and Delivery Route: Location Does Not Matter

Contact Info

Product

Resources

About